Health Condition 1: null- Pemphigus vulgaris
Conditions
Interventions
Intervention1: Dexamethasone cyclophosphamide pulse theapy: Infusion of 100 mg dexamethasone in 500 ml of 5% glucose will be given daily for three consecutive days, with 500mg cyclophosphamide infusio
Sponsors
Department of Science Technology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subject of either sex, aged 18-70 years presenting with vesiculobullous lesions on skin and/or oral erosions showing either - Histological features of suprabasal acantholysis and / or - Positive desmoglein 3 and/or desmoglein 1 levels 2. Pemphigus vulgaris of moderate to severe involvement (BSA >= 5%)
Exclusion criteria
Exclusion criteria: 1. Age 70 years 2. Unmarried individuals or those who have not completed family. 3. Pregnant or lactating women. 4. Patients with severe cardiac, renal or hepatic disease. 5. Autoimmune blistering disease other than PV. 6. Active, unhealed peptic ulcer within 3 months prior to randomization. 7. Inherited or acquired immune deficiency 8. Malignancy, lymphoproliferative diseases or previous total lymphoid irradiation. 9. Chronic or frequent drug resistant, bacterial infections or presence of severe active infection. 10. Bone marrow insufficiency. 11. Frequent and / or serious viral infections. 12. Systemic or invasive fungal disease within 2 years prior to randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the levels of lymphocyte subpopulation in pemphigus after dexamethasone cyclophosphamide therapy and dexamethasone pulse therapy. Timepoint: 1st, 2nd, 4th week, 3rd month and 6th month | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of disease activity in these patients with changes in these immunological parameters. Timepoint: 1st, 2nd, 4th week, 3rd month and 6th month | — |
Countries
India
Contacts
Public ContactDr Neetu Bhari
All India Institute of Medical Science
Outcome results
None listed